‘A commonly used asthma treatment appears to reduce the need for hospitalisations as well as recovery time for COVID-19 patients if given within seven days of symptoms appearing, researchers at the University of Oxford said on Tuesday (Feb 9).
‘The findings were made following a mid-stage study of the steroid budesonide, sold as Pulmicort by AstraZeneca and also used for treating smoker's lung.
‘The 28-day study of 146 patients suggested that inhaled budesonide reduced the risk of urgent care or hospitalisation by 90 per cent when compared with usual care, Oxford University said.’
Read here (Channel News Asia, Feb 10, 2021)
